Business

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Financial Post · October 15, 2026 at 9:00 a.m.

Potential first-in-class dual targeting inhibitor oral small molecule to enter Sanofi’s development pipeline, with phase 1 clinical study currently planned to begin in 2027 Salt Lake City, UT, Oct.

15, 2026 (GLOBE NEWSWI

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

More from Financial Post

Nest Wealth Asset Management Appoints Sean Tascatan as Chief Investment and Growth Officer as It Enters Its Next Phase of Evolution

Body of Waves, a New Artwork Only at teamLab Planets TOKYO, Unveiled

Tropic Grows Bookings 70% Year Over Year, Marking Sixth Straight Quarter of Sequential Growth

Thunder Bay Library Workers Begin Strike to Defend Jobs and Public Services: ‘We’re Prepared to Fight for as Long as It Takes’

More in Business

Nest Wealth Asset Management Appoints Sean Tascatan as Chief Investment and Growth Officer as It Enters Its Next Phase of Evolution

Body of Waves, a New Artwork Only at teamLab Planets TOKYO, Unveiled

Tropic Grows Bookings 70% Year Over Year, Marking Sixth Straight Quarter of Sequential Growth

Thunder Bay Library Workers Begin Strike to Defend Jobs and Public Services: ‘We’re Prepared to Fight for as Long as It Takes’

National Comedy Center Preserves Hundreds of Rare, Never-Before-Seen I Love Lucy Behind-the-Scenes Photographs and Early Pilot Script for 75th Anniversary

Samsung Canada Launches Ask Us Anything to Answer Canadians’ Questions About Foldable Phones